GlassScriptPhysician profile
Nishant Prasad
NPI 1811130404
$9,741.73
in general payments reported to CMS, 2019-2025
21 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $1,060 · 2021: $1,349 · 2022: $1,556 · 2023: $1,363 · 2024: $834 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,262 · Education: $51.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,262.41 |
| Education | $51.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,337.71 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Janssen Biotech, INC. | $2,094.39 | 2019-2023 | Symtuza |
| Gilead Sciences, INC. | $1,993.01 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Melinta Therapeutics, LLC | $608.24 | 2019-2025 | Rezzayo |
| Shionogi INC | $471.48 | 2019-2023 | Fetroja |
| Theratechnologies INC. | $376.77 | 2019-2024 | Egrifta Sv, Trogarzo, Egrifta |
| Abbvie INC. | $347.00 | 2022-2025 | |
| Janssen Products, LP | $322.46 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $227.38 | 2019-2025 | Nuzyra, Xhance |
| Insmed, INC. | $214.08 | 2019 | |
| Daiichi Sankyo INC. | $189.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $144.03 | 2021-2023 | Delstrigo, Pifeltro |
| Cumberland Pharmaceuticals, INC. | $114.93 | 2019-2023 | Vibativ |
| Pfizer INC. | $102.38 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $69.39 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.72 | 2025 | |
| Astellas Pharma US INC | $21.67 | 2022 | |
| Amgen INC. | $17.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishant Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.